Replies to post #12414 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Another thing the 2 of you completely brush off/attempt to overlook in your desperation to attempt to knock a stock neither of you admittedly even own...is prior to the FDA's decision to advise IPCI they were so blown away by phase 1 results that IPCI can skip phase III trials entirely...and prior to the FDA even granting fast-track designation which included the PODRAS tech...is the glaring simple fact that the FDA was/is well aware of the PODRAS enhancement and well aware that IPCI filed for the PODRAS patent...and that such patent should be granted sometime between august and October of this year going by how fast the patent office moves on such patents!

So feel free to explain why the FDA would even see fit to bother granting a fast-track designation incorporating the PODRAS tech or bother advising IPCI to skip phase III trials entirely and just submit bioequivalence knowing full well the PODRAS patent was filed a year in advance of those 2 recent FDA decisions?

There's no logical way to even attempt to explain why the FDA would even waste their own or IPCI's time making the 2 decisions they just did on Rexista considering the FDA has been privy to PODRAS tech platform being incorporated into Rexista the entire time...yet saw fit to grant the fast-track designation incorporating PODRAS prior to the PODRAS patent even being issued!

[BondsSF]

"We are pleased with the grant by the FDA of Fast Track status for Rexista(TM) Oxycodone XR incorporating our proprietary PODRAS(TM) technology which is being formulated to decrease the 'liking' of dose escalation and decrease or delay the attendant risk of respiratory depression in drug-naive individuals. The development of this product candidate could, if successful, decrease the desirability of taking more intact tablets than prescribed, potentially addressing an unmet need and possibly resulting in fewer accidental or intentional deaths," stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. "To the best of our knowledge, no other product currently approved for sale in the U.S. or Canada has demonstrated this potential."